

# Prescribing and Medicines Optimisation Guidance

---

Issue: 70

Date: 8<sup>th</sup> June 2022

- 1. MHRA: National Patient Safety Alert: NovoRapid PumpCart in the Roche Accu-Chek Insight insulin pump: risk of insulin leakage causing hyperglycaemia and diabetic ketoacidosis). 26<sup>th</sup> May 2022 [LINK](#)**

An alert to highlight reports of serious harm associated with insulin leakage for the NovoRapid PumpCart prefilled insulin cartridge in the Accu-Chek Insight Insulin pump. In some people, there were serious consequences including diabetic ketoacidosis.

- 2. MHRA: Antivirals or neutralising monoclonal antibodies for non-hospitalised patients with COVID-19 [LINK](#)**

Policy updated, effective from 13th June, to link to published DHSC report to advise on the patient groups likely to be at highest risk of deterioration, hospitalisation or death from COVID infection & confirms the groups potentially eligible for community based COVID treatment.

- 3. UHS Medicines Learning Portal: Ukrainian medicines resources [LINK](#)**

University Hospital Southampton (UHS) have gathered some resources to help healthcare professionals with medicines related issues associated with patients arriving from Ukraine.

- 4. Reminder : MHRA Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment (first published 26<sup>TH</sup> August 2020) [LINK](#)**

## Advice for healthcare professionals:

- an increased risk of multiple vertebral fractures has been reported in patients within 18 months of stopping or delaying ongoing denosumab 60mg treatment for osteoporosis; cases have been reported in patients in the UK
- patients with a previous vertebral fracture may be at highest risk

- evaluate a patient's individual factors for benefits and risks before initiating treatment with denosumab, particularly in patients at increased risk of vertebral fractures for example those with previous vertebral fracture
- patients should not stop denosumab without specialist review
- the optimal duration of denosumab treatment for osteoporosis has not been established; re-evaluate the need for continued treatment periodically based on the expected benefits and potential risks of denosumab on an individual patient basis, particularly after 5 or more years of use
- risks of long-term treatment with denosumab include rare cases of [osteonecrosis of the jaw](#) and [atypical femoral fractures](#); [osteonecrosis of the external auditory canal](#) has also been reported in association with denosumab

**Prepared by Anita Bhardwaj, Sue Wakelin and Dr Emma Harris  
On behalf of the Hampshire, Southampton and IoW CCG Medicines Optimisation  
Team**

*Previous bulletins can be found at: <https://gp-portal.westhampshireccg.nhs.uk/medicines/covid-19-medicines-information/covid-19-medicines-optimisation-bulletins/>*